Protein Tyrosine Phosphatases as Drug Targets: Strategies and Challenges of Inhibitor Development
2010; Future Science Ltd; Volume: 2; Issue: 10 Linguagem: Inglês
10.4155/fmc.10.241
ISSN1756-8927
Autores Tópico(s)Cytokine Signaling Pathways and Interactions
ResumoSeveral ‘classical’ protein tyrosine phosphatases are attractive therapeutic targets, including PTP1B for obesity and Type II diabetes; SHP2 for cancer and Lyp for rheumatoid arthritis. Progress has been made in identifying a broad range of chemically distinct inhibitors; however, developing selective and cell-permeable clinically useful compounds has proved challenging. Here the ongoing challenges and recent significant advances in the field are reviewed. Key novel compounds are highlighted and a perspective on the future of phosphatase inhibitor development is presented.
Referência(s)